Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis - PubMed (original) (raw)
. 2006 Jul 1;108(1):286-91.
doi: 10.1182/blood-2005-10-3969. Epub 2006 Jan 24.
Affiliations
- PMID: 16434489
- DOI: 10.1182/blood-2005-10-3969
Free article
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
Neil P Shah et al. Blood. 2006.
Free article
Abstract
Mastocytosis is associated with an activating mutation in the KIT oncoprotein (KITD816V) that results in autophosphorylation of the KIT receptor in a ligand-independent manner. This mutation is inherently resistant to imatinib and, to date, there remains no effective curative therapy for systemic mastocytosis associated with KITD816V. Dasatinib (BMS-354825) is a novel orally bioavailable SRC/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML). Pharmacokinetic analysis suggests that high nanomolar concentrations of dasatinib can be achieved safely in humans. In this study, we demonstrate significant inhibitory activity of dasatinib against both wild-type KIT and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays. Additionally, dasatinib leads to growth inhibition of a KITD816V-harboring human masto-cytosis cell line. Significantly, dasatinib selectively kills primary neoplastic bone marrow mast cells from patients with systemic mastocytosis while sparing other hematopoietic cells. Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of KIT by dasatinib. Based upon our results, further evaluation of dasatinib for the treatment of systemic masto-cytosis in clinical trials is warranted. Moreover, dasatinib may be of clinical utility in other disease settings driven by activating KIT mutations.
Similar articles
- Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Schittenhelm MM, et al. Cancer Res. 2006 Jan 1;66(1):473-81. doi: 10.1158/0008-5472.CAN-05-2050. Cancer Res. 2006. PMID: 16397263 - Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte AS, Barra FF, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Olalla Saad ST, Traina F. de Melo Campos P, et al. Leuk Res. 2014 Oct;38(10):1245-51. doi: 10.1016/j.leukres.2014.07.010. Epub 2014 Aug 1. Leuk Res. 2014. PMID: 25139846 - The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE. Tokarski JS, et al. Cancer Res. 2006 Jun 1;66(11):5790-7. doi: 10.1158/0008-5472.CAN-05-4187. Cancer Res. 2006. PMID: 16740718 - Overcoming kinase resistance in chronic myeloid leukemia.
Lee F, Fandi A, Voi M. Lee F, et al. Int J Biochem Cell Biol. 2008;40(3):334-43. doi: 10.1016/j.biocel.2007.10.001. Int J Biochem Cell Biol. 2008. PMID: 18401881 Review.
Cited by
- Management of Advanced Systemic Mastocytosis: Clinical Challenges.
Tremblay D, Wagner NE, Mascarenhas J. Tremblay D, et al. J Blood Med. 2024 Sep 11;15:421-433. doi: 10.2147/JBM.S366367. eCollection 2024. J Blood Med. 2024. PMID: 39279879 Free PMC article. Review. - HIF-1α-dependent upregulation of angiogenic factors by mechanical stimulation in retinal pigment epithelial cells.
Ashimori A, Higashijima F, Ogata T, Sakuma A, Hamada W, Sunada J, Aoki R, Mikuni M, Hayashi K, Wakuta M, Yoshimoto T, Minamoto A, Ko JA, Kimura K. Ashimori A, et al. Dis Model Mech. 2024 Apr 1;17(4):dmm050640. doi: 10.1242/dmm.050640. Epub 2024 May 1. Dis Model Mech. 2024. PMID: 38691000 Free PMC article. - Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.
Assi A, Farhat M, Hachem MCR, Zalaquett Z, Aoun M, Daher M, Sebaaly A, Kourie HR. Assi A, et al. J Bone Oncol. 2023 Nov 3;43:100511. doi: 10.1016/j.jbo.2023.100511. eCollection 2023 Dec. J Bone Oncol. 2023. PMID: 38058514 Free PMC article. Review. - c-Kit Receptor Maintains Sensory Axon Innervation of the Skin through Src Family Kinases.
Tuttle AM, Pomaville MB, Delgado KC, Wright KM, Nechiporuk AV. Tuttle AM, et al. J Neurosci. 2022 Sep 7;42(36):6835-6847. doi: 10.1523/JNEUROSCI.0618-22.2022. J Neurosci. 2022. PMID: 35882558 Free PMC article. - Avapritinib in the Treatment of Systemic Mastocytosis: an Update.
Below S, Michaelis LC. Below S, et al. Curr Hematol Malig Rep. 2021 Oct;16(5):464-472. doi: 10.1007/s11899-021-00650-4. Epub 2021 Sep 27. Curr Hematol Malig Rep. 2021. PMID: 34580817 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous